1. Home
  2. CLGN vs PULM Comparison

CLGN vs PULM Comparison

Compare CLGN & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$0.31

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$1.59

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLGN
PULM
Founded
2004
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
6.1M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
CLGN
PULM
Price
$0.31
$1.59
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
53.8K
7.6K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$7,910,000.00
Revenue This Year
$240.45
N/A
Revenue Next Year
$38.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5069.93
52 Week Low
$0.27
$1.16
52 Week High
$3.18
$5.50

Technical Indicators

Market Signals
Indicator
CLGN
PULM
Relative Strength Index (RSI) 46.32 38.97
Support Level $0.29 $1.21
Resistance Level $0.44 $1.55
Average True Range (ATR) 0.04 0.08
MACD 0.00 -0.02
Stochastic Oscillator 46.96 18.73

Price Performance

Historical Comparison
CLGN
PULM

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: